XBI Performance — State Street(R) SPDR(R) S&P(R) Biotech ETF
Data updated: 2026-09-11
XBI returned +29.82% year to date and +91.71% over one year to Jun 2026. Annualised returns are +24.11% over 3 years and +3.26% over 5 years. The fund beat its Health Care Equity category average: $100 invested three years ago grew to $191, against $138 for the category, and to $192 over one year, against $137. Volatility over the past three years was 25.54% a year. In the 12 months to Jun 2026 the fund took in a net $1.3B, and assets reached $10.73B.
XBI Growth of $100
What $100 invested in State Street(R) SPDR(R) S&P(R) Biotech ETF grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.
| Period | XBI | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $192 | $137 |
| 3 years (Jul 2023 – Jun 2026) | $191 | $138 |
| 5 years (Jul 2021 – Jun 2026) | $117 | $121 |
| Since data start (Jul 2019 – Jun 2026) | $182 | $182 |
XBI Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +29.82% |
| 1 year | +91.71% |
| 3 years (annualised) | +24.11% |
| 5 years (annualised) | +3.26% |
XBI Annual Returns
Calendar-year total returns of State Street(R) SPDR(R) S&P(R) Biotech ETF, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +29.82% |
| 2025 | +35.84% |
| 2024 | +1.09% |
| 2023 | +7.48% |
| 2022 | −25.76% |
| 2021 | −20.53% |
| 2020 | +48.20% |
| 2019 (Jul–Dec) | +8.44% |
XBI Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +2.3% | +2.1% | +0.2% | +2.8% | +4.1% | +15.8% | — | — | — | — | — | — |
| 2025 | +2.8% | −4.2% | −8.6% | +2.4% | −4.6% | +4.7% | +3.3% | +4.9% | +11.5% | +12.6% | +9.2% | −0.6% |
| 2024 | −1.9% | +12.4% | −3.4% | −11.1% | +5.3% | +4.3% | +6.8% | +2.3% | −2.4% | −1.9% | +2.6% | −9.5% |
| 2023 | +7.2% | −6.9% | −8.1% | +5.3% | +4.9% | −1.1% | +1.2% | −6.1% | −7.7% | −9.3% | +14.0% | +18.3% |
| 2022 | −16.3% | −4.0% | 0.0% | −18.0% | −6.8% | +7.9% | +9.2% | +3.3% | −5.2% | +3.5% | +2.0% | −0.8% |
| 2021 | +8.5% | −3.2% | −8.2% | +0.8% | −6.4% | +6.0% | −8.9% | +7.7% | −5.4% | −0.8% | −6.8% | −3.8% |
| 2020 | −6.5% | +0.2% | −13.1% | +20.4% | +10.9% | +8.1% | −2.6% | +2.4% | −0.2% | +1.0% | +18.3% | +5.9% |
| 2019 | — | — | — | — | — | — | −2.4% | −6.2% | −5.1% | +7.0% | +14.7% | +1.8% |
XBI Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 25.54%
- 3-year Sharpe ratio: 0.77 (vs 4.5% risk-free rate)
- Best month: +18.27% (Dec 2023)
- Worst month: −11.07% (Apr 2024)
XBI Fund Flows
Monthly money in and out of State Street(R) SPDR(R) S&P(R) Biotech ETF, from SEC Form N-PORT.
- 12-month net flow: $1.3B
- 12-month gross sales (incl. reinvestments): $30.8B
- Sales ÷ redemptions: 1.05×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $3.5B | $2.6B | $918.7M |
| May 2026 | $2.2B | $2.4B | −$223.6M |
| Apr 2026 | $3.3B | $2.7B | $633.3M |
| Mar 2026 | $2.9B | $3.5B | −$589.5M |
| Feb 2026 | $2.7B | $3.1B | −$443.2M |
| Jan 2026 | $2.6B | $2.3B | $307.4M |
| Dec 2025 | $2.4B | $2.8B | −$390.1M |
| Nov 2025 | $3.7B | $2.9B | $779.4M |
| Oct 2025 | $3.0B | $2.5B | $427.7M |
| Sep 2025 | $1.5B | $1.4B | $96.0M |
| Aug 2025 | $1.7B | $1.7B | $15.4M |
| Jul 2025 | $1.3B | $1.5B | −$200.2M |
XBI Assets Under Management
Net assets of State Street(R) SPDR(R) S&P(R) Biotech ETF by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $10.73B |
| 2026-03-31 | $7.43B |
| 2025-12-31 | $7.85B |
| 2025-09-30 | $5.71B |
| 2025-06-30 | $4.83B |
| 2025-03-31 | $5.12B |
| 2024-12-31 | $6.37B |
| 2024-09-30 | $7.70B |
| 2024-06-30 | $7.13B |
| 2024-03-31 | $7.55B |
| 2023-12-31 | $6.99B |
| 2023-09-30 | $5.50B |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.